Tardive Dyskinesia Risk From Newer Antispychotics Similar to Older Drugs: Study

The findings of a new study suggest that the risk of the muscular movement disorder tardive dyskinesia is no greater with newer atypical antipsychotics than it is with older drugs. 

The tardive dyskinesia study, published late last month by the National Institutes of Health, found that the rate of users of atypical antipsychotics, such as Seroquel, Risperdal and Zyprexa, who contracted tardive dyskinesia (TD) was little different from studies conducted in the 1980s on TD’s link to conventional atypical antipsychotics.

In a cohort study involving 352 psychiatric patients, researchers looked at the rate of the development of TD every six months over a period of four years. They found, contrary to the findings of some previous studies, that the rate of the onset of TD was about the same whether the patient was using conventional antipsychotics, or more traditional ones. Researchers said that previous studies were not primarily focused on TD.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Tardive dyskinesia is a neurological movement disorder that causes repetitive and involuntary movements of the lower face and limbs. Symptoms can include grimacing, chewing, smacking of lips, rapid eye movements and impaired finger movements. There is no known effective treatment of the disorder, and involuntary movements can become permanent, persisting after use of the drug has stopped.

The condition has become a focal point in a number of recent lawsuits over Reglan, a heartburn drug which has been linked to an increased tardive dyskinesia risk when taken for long periods of time. The complaints involve allegations that the manufacturers of Reglan and generic metoclopramide failed to adequately investigate and study the drug or warn about the potential risk of tardive dyskinesia from Reglan side effects.

2 Comments

  • SamSeptember 19, 2010 at 10:34 pm

    i got TD from this medicine is it to late for me to take legal action?

  • MomSeptember 12, 2010 at 3:33 am

    WHAT? So....who funded *this* study? So...when the FDA sent out a warning letter to AZ in July, 2010 specifically referring to AZ downplaying the very real possibility of Tardive Dyskinesia (esp. with children and the elderly and for a shorter amount of time on a lower dose)....that was all....par for the course????? BS, I say.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted today)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted yesterday)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.